Menu

  • Products & Technologies
  • Clinical Evidence
  • Media Kit
  • Reimbursement
  • Medtronic Academy

    • Evidence for sustained relief

    Outcomes from a 2023 PROCURA study1 show that differential target multiplexed (DTM™) SCS therapy results in an 86.0% upper limb pain (ULP) responder rate with DTM™ SCS at 12 months for an improvement rate ≥ 50% (n = 43).1

    See secondary outcomes

    PROCURA is an on-label, multicenter, observational clinical study using DTM™ SCS evaluating patients with intractable chronic upper limb pain (VAS ≥ 5 cm) at 11 sites across the United States.1

    Get the PROCURA study (open in new window)

    Upper limb pain relief†,‡

    Sustained upper limb pain relief with a mean VAS score of 1.45 cm at 12 months with DTM™ SCS (n = 43)

    Upper limb pain responder rate‡


    86% — ULP responder rate with DTM™ SCS at 12 months
    (≥ 50% improvement). (n = 43)

    Upper limb pain profound responder rate
    (≥ 80% ULP pain relief)‡


    70% — 7 out of 10 patients were profound ULP responders
    (≥ 80% relief) with DTM at 12 months.

    DTM therapy outcomes1

    Subjects reporting ≥ 50% pain relief

    91.5%

    at 3-month
    follow-up (n = 47)

    90.9%

    at 6-month
    follow-up (n = 44)

    86.0%

    at 12-month
    follow-up (n = 43)

    Quality-of-life outcomes§

    DTM™ SCS provides effective upper limb pain (ULP) relief through 12 months.

    • 86.0% ULP responder rate at 12 months
    • ULP visual analog scale (VAS) reduced by 79.8%
    • 29.6 point reduction in reported patient PDI scores with DTM™ SCS
    • 94.9% subject satisfaction rate as very satisfied with DTM™ SCS therapy at 12 months

    Talk with your Medtronic representative to learn more about SCS.